We are international
Donate
TEXT SIZE   

Frontline Treatments

03.06.05   REVLIMID®
REVLIMID®, a potent immunomodulatory derivative (IMiD) of thalidomide, induces apoptosis in resistant MM cell lines and patient cells and, more importantly, decreases binding of MM cells to bone marrow stromal cells.

05.11.04   VELCADE® (bortezomib) for Injection
VELCADE® is an antineoplastic agent available for intravenous injection (IV) use only. It has been approved by the FDA for the treatment of myeloma. Watch the "Ask the Expert" Videos from ASCO 2004 and Lymphoma Myeloma Conference 2004 on VELCADE® as treatment and in research.

04.18.04   Thalidomide
Helpful information about Thalidomide Therapy for patients and caregivers, including clinical trials with THALOMID®. Watch "Ask the Expert" videos from ASCO 2004 and the Lymphoma Myeloma Conference 2004.

04.18.04   The Myeloma Matrix
A comprehensive guide to new drugs in development for myeloma.

06.05.07   Dexamethasone
Dexamethasone, an adrenal corticosteroid, is used to treat multiple myeloma.

04.18.04   Radiation Therapy
Radiation is often used for treatment of myeloma bone disease.

11.06.09   The Effect of Novel Antimyeloma Agents on Bone Metabolism
XIIth International Myeloma Workshop in Washington, DC
Evangelos Terpos, M.D.
General Air Force Hospital
Athens, Greece

11.06.09   Managing Side Effects of Novel Agents
IMF Nurse Leadership Board Member Deborah Doss, R.N., OCN Dana Farber Cancer Institute Boston, MA